Genetic Signature Identifies Patients With More Aggressive Triple-Negative Cancers, University of Chicago Study

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

A new test has the potential to help physicians identify patients with the most lethal forms of triple-negative breast cancer, a disease which requires aggressive and innovative treatment. The test, described in the journal PLOS ONE, was able to distinguish between patients with a good or poor prognosis, even within groups of patients already stratified by existing tests such as MammaPrint and Oncotype, as well as to extend its predictions to patients with more advanced or difficult-to-treat cancers.

Hey, check out all the engineering jobs. Post your resume today!

Back to news